Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …

Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …

Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-
CoV-2 infection is crucial for understanding immune protection and identifying targets for …

Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and
young children that may lead to hospitalizations and a substantial number of outpatient …

Bronchiolitis is an acute respiratory illness that is the leading cause of hospitalization in
young children. This document aims to update the consensus document published in 2014 …

Respiratory syncytial virus (RSV) is a single-stranded negative-sense RNA virus that is the
primary etiologic pathogen of bronchitis and pneumonia in infants and the elderly. Currently …

Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …

After decades of work, several interventions to prevent severe respiratory syncytial virus
(RSV) disease in high-risk infant and older adult populations have finally been approved …

Objective The high burden associated with respiratory syncytial virus (RSV) has made the
development of RSV vaccine (s) a global health high priority. This review summarizes the …

The route of administration of a therapeutic agent has a substantial impact on its success.
Therapeutic antibodies are usually administered systemically, either directly by intravenous …